The company: FDA approves imetelstat for low- to intermediate-1 risk myelodysplastic syndromes with Nov 6Regulatory decisionGeron CorporationimetelstatRecord notice
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Geron halts Phase 3 IMpactMF trial of imetelstat in myelofibrosisOct 28Clinical readoutGeron Corporationimetelstat
Geron reports Q2 2026 results as RYTELO revenue climbs to $57.5 millionAug 6Quarterly updateGeron Corporationimetelstat